Sarepta Therapeutics announced the FDA's Pediatric Advisory Committee and the Pediatric Ethics Subcommittee will meet on May 18 to discuss a referral by an Institutional Review Board of the Phase III Essence study evaluating exon skipping drugs SRP-4045 and SRP-4053, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. As planned, when 75 DMD boys aged 7-13 years had been enrolled for 48 weeks, an IRB would review to determine any protocol modifications to progress to 96 weeks of treatment, the analyst adds. He maintains an Overweight rating on Sarepta with a $43 price target ahead of the company's Q1 results on April 27. Tenthoff models for $14M of Exondys51 sales in the quarter.